stockportfolio.pro
AbbVie Inc. (ABBV)
Healthcare · Drug Manufacturers - General · NYSE
AbbVie Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $25.64B | $28.22B | $32.75B | $33.27B | $45.80B | $56.20B | $58.05B | $54.32B | $56.33B | $61.16B |
| Gross profit | $19.81B | $21.17B | $25.04B | $25.83B | $30.42B | $38.75B | $40.64B | $33.90B | $39.43B | $42.96B |
| Net income | $5.95B | $5.31B | $5.69B | $7.88B | $4.62B | $11.54B | $11.84B | $4.86B | $4.28B | $4.23B |
| Net margin | 23.2% | 18.8% | 17.4% | 23.7% | 10.1% | 20.5% | 20.4% | 9.0% | 7.6% | 6.9% |
Source: AbbVie Inc. SEC filings (10-K). 15 years of history available in the interactive view.
What growth is priced into ABBV stock?
At today's market cap of $398.27B, AbbVie Inc. is priced for free-cash-flow growth of about 9.2% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $17.82B from the FY ending 2025-12-31). For comparison, free cash flow actually grew 1.2%/yr over the last five fiscal years and revenue 6%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 15 years of AbbVie Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track ABBV in your portfolio →
AbbVie Inc. financial history by metric
About AbbVie Inc.
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
AbbVie Inc. — frequently asked questions
What is AbbVie Inc.'s revenue?
AbbVie Inc. (ABBV) reported revenue of $61.16B for fiscal year 2025, up 8.6% from the prior year, according to its SEC filings.
Is AbbVie Inc. profitable?
Yes. ABBV earned net income of $4.23B in fiscal 2025, a net margin of 6.9%.
What is ABBV's P/E ratio?
AbbVie Inc. trades at a price-to-earnings ratio of about 111.0 based on the latest data in our nightly-refreshed cache.
How fast is AbbVie Inc. growing?
ABBV's revenue grew at roughly 6.0% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does AbbVie Inc. have?
As of fiscal year 2025, ABBV carried roughly $67.00B in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is AbbVie Inc.'s gross margin?
ABBV's gross margin was 70.2% in fiscal 2025 — gross profit of $42.96B on revenue of $61.16B.
What is AbbVie Inc.'s market cap?
AbbVie Inc. (ABBV) has a market capitalization of about $398.27B, based on the latest data in our nightly-refreshed cache.
When does AbbVie Inc.'s fiscal year end?
ABBV's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into ABBV stock?
At today's market cap of $398.27B, AbbVie Inc. is priced for free-cash-flow growth of about 9.2% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $17.82B from the FY ending 2025-12-31). For comparison, free cash flow actually grew 1.2%/yr over the last five fiscal years and revenue 6%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from AbbVie Inc.'s official SEC filings (10-K and 10-Q), covering 15 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.